Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone, Cristina Rondinone, Boaz Hirshberg, Lutz Jermutus. Lancet 2018
Times Cited: 85
Times Cited: 85
Times Cited
Times Co-cited
Similarity
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
54
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
47
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
43
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Joachim Tillner, Maximilian G Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart,[...]. Diabetes Obes Metab 2019
Joachim Tillner, Maximilian G Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart,[...]. Diabetes Obes Metab 2019
75
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
37
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
35
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
34
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
31
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
30
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
27
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
25
Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.
Tricia M Tan, Benjamin C T Field, Katherine A McCullough, Rachel C Troke, Edward S Chambers, Victoria Salem, Juan Gonzalez Maffe, Kevin C R Baynes, Akila De Silva, Alexander Viardot,[...]. Diabetes 2013
Tricia M Tan, Benjamin C T Field, Katherine A McCullough, Rachel C Troke, Edward S Chambers, Victoria Salem, Juan Gonzalez Maffe, Kevin C R Baynes, Akila De Silva, Alexander Viardot,[...]. Diabetes 2013
24
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
24
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
28
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
22
The New Biology and Pharmacology of Glucagon.
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
22
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.
Jaimini Cegla, Rachel C Troke, Ben Jones, George Tharakan, Julia Kenkre, Katherine A McCullough, Chung Thong Lim, Nassim Parvizi, Mohamed Hussein, Edward S Chambers,[...]. Diabetes 2014
Jaimini Cegla, Rachel C Troke, Ben Jones, George Tharakan, Julia Kenkre, Katherine A McCullough, Chung Thong Lim, Nassim Parvizi, Mohamed Hussein, Edward S Chambers,[...]. Diabetes 2014
22
GLP-1/glucagon receptor co-agonism for treatment of obesity.
Miguel A Sánchez-Garrido, Sara J Brandt, Christoffer Clemmensen, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp. Diabetologia 2017
Miguel A Sánchez-Garrido, Sara J Brandt, Christoffer Clemmensen, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp. Diabetologia 2017
26
The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers.
Tricia Tan, Preeshila Behary, George Tharakan, James Minnion, Werd Al-Najim, Nicolai J Wewer Albrechtsen, Jens J Holst, Stephen R Bloom. J Clin Endocrinol Metab 2017
Tricia Tan, Preeshila Behary, George Tharakan, James Minnion, Werd Al-Najim, Nicolai J Wewer Albrechtsen, Jens J Holst, Stephen R Bloom. J Clin Endocrinol Metab 2017
41
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
25
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.
Katie Wynne, Adrian J Park, Caroline J Small, Michael Patterson, Sandra M Ellis, Kevin G Murphy, Alison M Wren, Gary S Frost, Karim Meeran, Mohammad A Ghatei,[...]. Diabetes 2005
Katie Wynne, Adrian J Park, Caroline J Small, Michael Patterson, Sandra M Ellis, Kevin G Murphy, Alison M Wren, Gary S Frost, Karim Meeran, Mohammad A Ghatei,[...]. Diabetes 2005
18
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller, Susanna M Hofmann. Mol Metab 2017
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller, Susanna M Hofmann. Mol Metab 2017
31
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.
K Wynne, A J Park, C J Small, K Meeran, M A Ghatei, G S Frost, S R Bloom. Int J Obes (Lond) 2006
K Wynne, A J Park, C J Small, K Meeran, M A Ghatei, G S Frost, S R Bloom. Int J Obes (Lond) 2006
17
The metabolic actions of glucagon revisited.
Kirk M Habegger, Kristy M Heppner, Nori Geary, Timothy J Bartness, Richard DiMarchi, Matthias H Tschöp. Nat Rev Endocrinol 2010
Kirk M Habegger, Kristy M Heppner, Nori Geary, Timothy J Bartness, Richard DiMarchi, Matthias H Tschöp. Nat Rev Endocrinol 2010
17
Oxyntomodulin suppresses appetite and reduces food intake in humans.
Mark A Cohen, Sandra M Ellis, Carel W Le Roux, Rachel L Batterham, Adrian Park, Michael Patterson, Gary S Frost, Mohammad A Ghatei, Stephen R Bloom. J Clin Endocrinol Metab 2003
Mark A Cohen, Sandra M Ellis, Carel W Le Roux, Rachel L Batterham, Adrian Park, Michael Patterson, Gary S Frost, Mohammad A Ghatei, Stephen R Bloom. J Clin Endocrinol Metab 2003
16
Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Nicola M Neary, Caroline J Small, Maralyn R Druce, Adrian J Park, Sandra M Ellis, Nina M Semjonous, Catherine L Dakin, Karin Filipsson, Fang Wang, Aysha S Kent,[...]. Endocrinology 2005
Nicola M Neary, Caroline J Small, Maralyn R Druce, Adrian J Park, Sandra M Ellis, Nina M Semjonous, Catherine L Dakin, Karin Filipsson, Fang Wang, Aysha S Kent,[...]. Endocrinology 2005
15
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
Megan E Capozzi, Richard D DiMarchi, Matthias H Tschöp, Brian Finan, Jonathan E Campbell. Endocr Rev 2018
Megan E Capozzi, Richard D DiMarchi, Matthias H Tschöp, Brian Finan, Jonathan E Campbell. Endocr Rev 2018
26
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda,[...]. J Med Chem 2017
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda,[...]. J Med Chem 2017
24
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
M A Nauck, M M Heimesaat, C Orskov, J J Holst, R Ebert, W Creutzfeldt. J Clin Invest 1993
M A Nauck, M M Heimesaat, C Orskov, J J Holst, R Ebert, W Creutzfeldt. J Clin Invest 1993
15
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
15
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
15
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
14
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Daniel J Drucker. Cell Metab 2018
Daniel J Drucker. Cell Metab 2018
14
Inhibition of food intake in obese subjects by peptide YY3-36.
Rachel L Batterham, Mark A Cohen, Sandra M Ellis, Carel W Le Roux, Dominic J Withers, Gary S Frost, Mohammad A Ghatei, Stephen R Bloom. N Engl J Med 2003
Rachel L Batterham, Mark A Cohen, Sandra M Ellis, Carel W Le Roux, Dominic J Withers, Gary S Frost, Mohammad A Ghatei, Stephen R Bloom. N Engl J Med 2003
12
Fibroblast growth factor 21 mediates specific glucagon actions.
Kirk M Habegger, Kerstin Stemmer, Christine Cheng, Timo D Müller, Kristy M Heppner, Nickki Ottaway, Jenna Holland, Jazzminn L Hembree, David Smiley, Vasily Gelfanov,[...]. Diabetes 2013
Kirk M Habegger, Kerstin Stemmer, Christine Cheng, Timo D Müller, Kristy M Heppner, Nickki Ottaway, Jenna Holland, Jazzminn L Hembree, David Smiley, Vasily Gelfanov,[...]. Diabetes 2013
12
Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
14
Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
12
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Pia K Nørregaard, Maria A Deryabina, Pernille Tofteng Shelton, Jacob U Fog, Jens R Daugaard, Per-Olof Eriksson, Lone F Larsen, Lene Jessen. Diabetes Obes Metab 2018
Pia K Nørregaard, Maria A Deryabina, Pernille Tofteng Shelton, Jacob U Fog, Jens R Daugaard, Per-Olof Eriksson, Lone F Larsen, Lene Jessen. Diabetes Obes Metab 2018
29
Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
12
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
22
Gut hormone polyagonists for the treatment of type 2 diabetes.
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
29
A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
11
11
Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
11
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
A Flint, A Raben, A Astrup, J J Holst. J Clin Invest 1998
11
Gut hormone PYY(3-36) physiologically inhibits food intake.
Rachel L Batterham, Michael A Cowley, Caroline J Small, Herbert Herzog, Mark A Cohen, Catherine L Dakin, Alison M Wren, Audrey E Brynes, Malcolm J Low, Mohammad A Ghatei,[...]. Nature 2002
Rachel L Batterham, Michael A Cowley, Caroline J Small, Herbert Herzog, Mark A Cohen, Catherine L Dakin, Alison M Wren, Audrey E Brynes, Malcolm J Low, Mohammad A Ghatei,[...]. Nature 2002
11
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi, Mark D Erion, Jas Gidda, Nancy A Thornberry, Matthias H Tschöp,[...]. Biopolymers 2012
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi, Mark D Erion, Jas Gidda, Nancy A Thornberry, Matthias H Tschöp,[...]. Biopolymers 2012
15
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, Marcella Petrone, Wenji Pu, Cristina Rondinone, Lutz Jermutus, Boaz Hirshberg. Br J Clin Pharmacol 2018
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, Marcella Petrone, Wenji Pu, Cristina Rondinone, Lutz Jermutus, Boaz Hirshberg. Br J Clin Pharmacol 2018
58
Targeted estrogen delivery reverses the metabolic syndrome.
Brian Finan, Bin Yang, Nickki Ottaway, Kerstin Stemmer, Timo D Müller, Chun-Xia Yi, Kirk Habegger, Sonja C Schriever, Cristina García-Cáceres, Dhiraj G Kabra,[...]. Nat Med 2012
Brian Finan, Bin Yang, Nickki Ottaway, Kerstin Stemmer, Timo D Müller, Chun-Xia Yi, Kirk Habegger, Sonja C Schriever, Cristina García-Cáceres, Dhiraj G Kabra,[...]. Nat Med 2012
11
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz,[...]. Diabetes Care 2016
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz,[...]. Diabetes Care 2016
11
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.